4°³ ÀÌ»óÀÇ ´Ù¹ß¼º ÀüÀ̼º ³úÁ¾¾çÀÇ Á¤À§Àû ¹æ»ç¼±¼ö¼ú°ú Àü³ú ¹æ»ç¼±Á¶»çÀÇ ºñ±³
Comparison of Stereotactic Radiosurgery and Whole Brain Radiotherapy in Patients with Four or More Brain Metastases
±èöÁø, ¹é¹Ì¿µ, ¹Ú¼º±¤, ¾È±âÁ¤, Á¶Èï·¡,
¼Ò¼Ó »ó¼¼Á¤º¸
±èöÁø ( Kim Cheol-Jin ) - ÀÎÁ¦´ëÇб³ Àǰú´ëÇÐ ¹æ»ç¼±Á¾¾çÇб³½Ç
¹é¹Ì¿µ ( Baek Mi-Young ) - ÀÎÁ¦´ëÇб³ Àǰú´ëÇÐ ¹æ»ç¼±°úÇб³½Ç
¹Ú¼º±¤ ( Park Sung-Kwang ) - ÀÎÁ¦´ëÇб³ Àǰú´ëÇÐ ¹æ»ç¼±Á¾¾çÇб³½Ç
¾È±âÁ¤ ( Ahn Ki-Jung ) - ÀÎÁ¦´ëÇб³ Àǰú´ëÇÐ ¹æ»ç¼±Á¾¾çÇб³½Ç
Á¶Èï·¡ ( Cho Heung-Lae ) - ÀÎÁ¦´ëÇб³ Àǰú´ëÇÐ ¹æ»ç¼±Á¾¾çÇб³½Ç
KMID : 0859320090270030163
Abstract
¸ñÀû : 4°³ ÀÌ»óÀÇ ´Ù¹ß¼º ÀüÀ̼º ³úÁ¾¾ç¿¡¼ Á¤À§Àû ¹æ»ç¼±¼ö¼úÀÇ È¿¿ë¼º¿¡ ´ëÇØ¼ °ËÁõÇϱâ À§ÇÏ¿© ÈÄÇâÀûÀ¸·Î ½ÃÇàÇÏ¿´´Ù.
´ë»ó ¹× ¹æ¹ý : 2004³â 1¿ùºÎÅÍ 2006³â 12¿ù±îÁö º»¿ø¿¡¼ 4°³ ÀÌ»óÀÇ ´Ù¹ß¼º ÀüÀ̼º ³úÁ¾¾çÀ¸·Î Áø´ÜµÇ¾î Á¤À§Àû ¹æ»ç¼±¼ö¼úÀ» ¹ÞÀº 29¸íÀÇ È¯ÀÚ¿Í Àü³ú ¹æ»ç¼±Á¶»ç¸¦ ¹ÞÀº 39¸íÀÇ È¯ÀÚ¸¦ ´ë»óÀ¸·Î ÈÄÇâÀûÀ¸·Î ºÐ¼®ÇÏ¿´´Ù. ¼Ò¼¼Æ÷ Æó¾Ï°ú Èæ»öÁ¾À¸·Î Áø´Ü¹ÞÀº ȯÀÚ´Â Á¦¿ÜÇÏ¿´°í, ¿ø¹ß º´¼Ò´Â Á¤À§Àû ¹æ»ç¼±¼ö¼ú±º¿¡¼´Â Æó¾ÏÀÌ 69.0%, À¯¹æ¾ÏÀÌ 13.8%¿´°í, Àü³ú ¹æ»ç¼±Á¶»ç±º¿¡¼´Â Æó¾ÏÀÌ 64.1%, À¯¹æ¾ÏÀÌ 15.4%, ´ëÀå-Á÷Àå¾ÏÀÌ 12.8%¿´´Ù. Á¤À§Àû ¹æ»ç¼±¼ö¼úÀº °¨¸¶³ªÀÌÇÁ¸¦ ÀÌ¿ëÇÏ¿© ½Ã¼úÇÏ¿´°í, 50% µî¼±·® °î¼±¿¡ 10¡20 Gy¸¦ 1ȸ Á¶»çÇÏ¿´´Ù. Àü³ú ¹æ»ç¼±Á¶»ç´Â 30 Gy, 10ȸ ºÐÇÒÁ¶»ç ÇÏ¿´´Ù. Ä¡·á ÈÄ ³ú ÀÚ±â°ø¸í¿µ»ó ¶Ç´Â Á¶¿µ Áõ° ÄÄÇ»ÅÍ ´ÜÃþÃÔ¿µÀ» ½ÃÇàÇÏ¿© µÎ ±º¿¡¼ Ä¡·á ÈÄ ÀüÀ̼º ³úÁ¾¾çÀÌ ÁøÇàµÇ±â±îÁö °É¸° ±â°£°ú Àüü »ýÁ¸À²¿¡ ´ëÇØ ºñ±³ ºÐ¼®ÇÏ¿´´Ù.
°á°ú : µÎ ±ºÀÇ Ãßô °üÂû ±â°£Àº 2°³¿ù¿¡¼ 23°³¿ùÀ̾ú°í, Á¤À§Àû ¹æ»ç¼±¼ö¼ú±ºÀÇ ÃßÀû°üÂû ±â°£ Áß¾Ó°ªÀº 5°³¿ù, Àü³ú ¹æ»ç¼±Á¶»ç±ºÀÇ °æ¿ì¿¡´Â 6°³¿ùÀ̾ú´Ù. ³úÀüÀÌ ¼ýÀÚÀÇ Áß¾Ó°ªÀÌ Á¤À§Àû ¹æ»ç¼±¼ö¼ú±º¿¡¼´Â 6°³, Àü³ú ¹æ»ç¼±Á¶»ç±º¿¡¼´Â 5°³¿´´Ù. ÀüÀ̼º ³úÁ¾¾çÀÇ ÁøÇàÀ» ¾ïÁ¦ÇÏ´Â È¿°ú¸¦ º¸¿©ÁÖ´Â µÎ°³³» ¹«ÁøÇà »ýÁ¸À²Àº Á¤À§Àû ¹æ»ç¼±¼ö¼ú±º¿¡¼´Â 5.1°³¿ù, Àü³ú ¹æ»ç¼±Á¶»ç±º¿¡¼´Â 6.1°³¿ùÀ̾ú°í, Á¤À§Àû ¹æ»ç¼±¼ö¼úÀ» ½ÃÇàÇÑ È¯ÀÚµéÀÇ Àüü »ýÁ¸À²ÀÇ Áß¾Ó°ªÀº 5.6°³¿ù, Àü³ú ¹æ»ç¼±Á¶»ç¸¦ ½ÃÇàÇÑ È¯ÀÚµéÀº 7.2°³¿ùÀ̾ú´Ù.
°á·Ð : 4°³ ÀÌ»óÀÇ ´Ù¹ß¼º ³ú ÀüÀÌ¿¡ ÀÖ¾î¼ Á¤À§Àû ¹æ»ç¼±¼ö¼úÀº Àü³ú ¹æ»ç¼±Á¶»ç¿¡ ºñÇØ ±× È¿¿ë¼ºÀÌ ³·À¸¸ç Àü³ú ¹æ»ç¼±Á¶»ç¸¦ ½ÃÇàÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÒ °ÍÀ¸·Î ÆÇ´ÜµÈ´Ù.
Purpose: This study was a retrospective evaluation of the efficacy of stereotactic radiosurgery (SRS) in patients with >4 metastases to the brain.
Materials and Methods : Between January 2004 and December 2006, 68 patients with ¡Ã4 multiple brain metastases were included and reviewed retrospectively. Twenty-nine patients received SRS and 39 patients received whole brain radiotherapy (WBRT). Patients with small cell lung cancers and melanomas were excluded. The primary lesions were non-small cell lung cancer (69.0%) and breast cancer (13.8%) in the SRS group and non-small cell lung cancer (64.1%), breast cancer (15.4%), colorectal cancer (12.8%), esophageal cancer (5.1%) in the WBRT group. SRS involved gamma-knife radiosurgery and delivered 10~20 Gy (median, 16 Gy) in a single fraction with a 50% marginal dose. WBRT was delivered daily in 3 Gy fractions, for a total of 30 Gy. After completion of treatment, a follow-up brain MRI or a contrast-enhanced brain CT was reviewed. The overall survival and intracranial progression-free survival were compared in each group.
Results: The median follow-up period was 5 months (range, 2~19 months) in the SRS group and 6 months (range, 4~23 months) in the WBRT group. The mean number of metastatic lesions in the SRS and WBRT groups was 6 and 5, respectively. The intracranial progression-free survival and overall survival in the SRS group was 5.1 and 5.6 months, respectively, in comparison to 6.1 and 7.2 months, respectively, in the WBRT group.
Conclusion: SRS was less effective than WBRT in the treatment of patients with >4 metastases to the brain.
Ű¿öµå
´Ù¹ß¼º ³úÀüÀÌ;Á¤À§Àû ¹æ»ç¼±¼ö¼ú;Àü³ú ¹æ»ç¼±Á¶»ç
Multiple brain metastases;Stereotactic radiosurgery;Whole brain radiotherapy
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸